Target (CBDY) Cash & Equivalents (2013 - 2026)
Target (CBDY) reported Cash & Equivalents of $209897.0 for Q1 2026, down 73.15% year-over-year from $781703.0 in Q1 2025, and up 109.04% quarter-over-quarter from $100410.0 in Q4 2025.
Target (CBDY) Cash & Equivalents (2013 - 2026) Analysis & Trends
Target (CBDY) has 14 years of Cash & Equivalents data on file, last reported at $209897.0 in Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $209897.0, down 73.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $209897.0 (down 73.15% YoY), and the FY2025 annual result was $100410.0, down 94.65% from the prior year.
- Cash & Equivalents climbed to $209897.0 in Q1 2026 per CBDY's latest filing, from $100410.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $1.9 million in Q4 2024 and troughed at $57833.0 in Q1 2023.
- A 5-year average of $648288.1 and a median of $453922.0 in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 1203.87% in 2024, then plunged 94.65% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $232333.0 in 2022, then jumped by 220.67% to $745019.0 in 2023, then surged by 152.04% to $1.9 million in 2024, then sank by 94.65% to $100410.0 in 2025, then surged by 109.04% to $209897.0 in 2026.
- Business Quant data shows CBDY's Cash & Equivalents at $209897.0 in Q1 2026, $100410.0 in Q4 2025, and $337488.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 3.74 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.94 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 1.28 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 40.42 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 266.50 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 428.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 351.55 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 222.27 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 498.58 Mn |
| 10 | Target | - | - | 191,787.00 | 209,897.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 209,897.00 |
| Dec 31, 2025 | 100,410.00 |
| Sep 30, 2025 | 337,488.00 |
| Jun 30, 2025 | 845,927.00 |
| Mar 31, 2025 | 781,703.00 |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 754,070.00 |
| Dec 31, 2023 | 745,019.00 |
| Sep 30, 2023 | 453,922.00 |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 57,833.00 |
| Dec 31, 2022 | 232,333.00 |
| Sep 30, 2022 | 206,095.00 |
| Jun 30, 2022 | 123,132.00 |
| Mar 31, 2022 | 203,674.00 |
| Dec 31, 2021 | 122,151.00 |
| Sep 30, 2021 | 54,205.00 |
| Jun 30, 2021 | 96,641.00 |